Break the fast? Update on patient preparation for cholesterol testing.

Area of Science:

• Cardiology
• Preventive Medicine
• Clinical Chemistry

Background:

• Dyslipidemia screening is crucial for coronary artery disease risk assessment.
• Management of lipid-lowering medications is a primary care focus.
• Recent evidence challenges the necessity of fasting for lipid testing.

Purpose of the Study:

• To update the understanding of nonfasting versus fasting lipid testing.
• To evaluate the impact on patient compliance, safety, and clinical assessment.
• To provide evidence-based recommendations for cholesterol testing protocols.

Main Methods:

• Review of current evidence regarding fasting status and lipid level variations.
• Assessment of clinical implications for different patient populations.
• Classification of evidence quality based on established guidelines (Canadian Task Force on Preventive Health Care).

Main Results:

• Total cholesterol, HDL cholesterol, and non-HDL cholesterol show minimal variation (average 2%) with fasting status.
• Nonfasting cholesterol measurement is a suitable alternative for routine screening.
• Fasting remains important for monitoring triglycerides and LDL cholesterol in patients on lipid-lowering therapy.
• Fasting may pose safety risks (hypoglycemia) for patients with diabetes.

Conclusions:

• Fasting for routine lipid level determination is largely unnecessary for risk stratification.
• Nonfasting lipid testing can enhance patient compliance and safety.
• Clinical decisions should consider the specific context, such as diabetes management and medication monitoring.